Dr. Volker Gerdts, VIDO Director

USask’s VIDO begins COVID-19 vaccine clinical trials at CCfV

Posted on

The first volunteers have been selected for a vaccine trial of COVAC-2, a COVID-19 vaccine developed by the Vaccine and infectious Disease Organization (VIDO) at the University of Saskatchewan (USask).

“We are excited to start clinical trials,” said VIDO Director Dr. Volker Gerdts. “Our team has worked hard to advance the development of this vaccine to help combat the COVID-19 pandemic.” 

The trial was designed as a combined Phase 1/Phase 2 study. Phase 1 will vaccinate 108 healthy volunteers in a placebo-controlled study at the Canadian Center for Vaccinology (CCfV) in Halifax. Two doses will be administered to each volunteer 28 days apart….


Read More Impact Stories

Posted on
For patients with neuroblastoma, one of the most common solid tumours in children, disease outcomes can vary widely. Some children [...]
Posted on
McMaster researchers have developed the first COVID rapid test for community wastewater, which will make early warning surveillance of infectious [...]
Posted on
Study shows limited impact of pandemic on mental health, underlining strength of human resilience. COVID-19 has taken a relatively limited [...]